Abstract

Mitochondrial (mt) DNA depletion and oxidative mtDNA damage have been implicated in the process of pathological cardiac remodeling. Whether these features are present in the early phase of maladaptive cardiac remodeling, that is, during compensated cardiac hypertrophy, is still unknown.We compared the morphologic and molecular features of mt biogenesis and markers of oxidative stress in human heart from adult subjects with compensated hypertrophic cardiomyopathy and heart failure. We have shown that mtDNA depletion is a constant feature of both conditions. A quantitative loss of mtDNA content was associated with significant down-regulation of selected modulators of mt biogenesis and decreased expression of proteins involved in mtDNA maintenance. Interestingly, mtDNA depletion characterized also the end-stage phase of cardiomyopathies due to a primary mtDNA defect. Oxidative stress damage was detected only in failing myocardium.

Highlights

  • We looked for changes in mitochondrial biogenesis and oxidative stress in hypertrophic nonfailing and failing hearts associated with a primary mitochondrial DNA (mtDNA) defects

  • The mean ejection fraction (EF) in Heart failure (HF) group was lower than 25% while it was within normal limits in hypertrophic cardiomyopathy (HCM) and NHF groups, as expected

  • We showed that mtDNA depletion and decreased levels of proteins involved in mtDNA maintenance are common features to both conditions, suggesting that impaired mitochondrial biogenesis is an early event in cardiac hypertrophic remodeling. mtDNA depletion in HCM was more evident in the total heart homogenate as compared with dissected cardiac myocytes

Read more

Summary

Introduction

Abbreviations: HF, heart failure; LV, left ventricular; OXPHOS, oxidative phosphorylation; mtDNA, mitochondrial DNA; MIC, mitochondrial cardiomyopathies; LCM, laser capture microdissection; COX, cytochrome c oxidase; SDH, succinate dehydrogenase; TEM, transmission electron microscopy; PPARα, peroxisome proliferator-activated receptor alpha PPARA; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1 alpha, PPARGC1A; NPPA, natriuretic peptide A; NRF1, nuclear respiratory factor 1; ERRα, estrogen-related receptor alpha ESRRA; TFAM, mitochondrial transcription factor A; POLG, polymerase (DNA directed) gamma; HPRT1, hypoxanthine phosphoribosyltransferase 1; SDS-PAGE, sodiumdodecylsulphate–polyacrylamide gel electrophoresis; PVDF, polyvinylidene fluoride; DNPH, 2,4-dinitrophenylhydrazine; DNP, antidinitrophenyl; CAT, catalase; GPx, glutathione peroxidase; NADPH, nicotinamide adenine dinucleotide phosphate; SOD2, superoxide dismutase 2; MDA, malondialdehyde.

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call